HEPLISAV-B achieved preliminary quarterly net product revenue of $71M for the fourth quarter of 2024, an increase of 39% compared to $51M for the fourth quarter of 2023. Q4 revenue consensus $71.71M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.